Ozmosi | VC-004 Drug Profile

Product Description

For NTRK fusion-positive locally advanced/metastatic solid tumors (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04614740)

Mechanisms of Action: TRKA Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Jiangsu Weikel Pharmaceutical Technology Co., Ltd.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for VC-004

Countries in Clinic: China

Active Clinical Trial Count: 6

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Oncology Solid Tumor Unspecified

Phase 1: Healthy Volunteers

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
NCT06658353	VC004-301	P3	Recruiting	Oncology Solid Tumor Unspecified	2026-12-30	12%	2025-03-21	Primary Endpoints\|Start Date\|Treatments\|Trial Status
CTR20243410	CTR20243410	P1	Completed	Healthy Volunteers\|Oncology Solid Tumor Unspecified	2024-10-31		2025-04-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
NCT06619951	VC004-106	P1	Completed	Oncology Solid Tumor Unspecified\|Healthy Volunteers	2024-10-31	12%	2024-12-12	Primary Completion Date\|Primary Endpoints\|Start Date\|Study Completion Date\|Treatments\|Trial Status
CTR20242528	CTR20242528	P1	Completed	Healthy Volunteers\|Oncology Solid Tumor Unspecified	2024-08-26		2025-04-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
NCT06529445	VC004-105	P1	Completed	Oncology Solid Tumor Unspecified\|Healthy Volunteers	2024-08-26		2024-08-30	Primary Completion Date\|Primary Endpoints\|Start Date\|Study Completion Date\|Treatments\|Trial Status
CTR20223032	CTR20223032	P1	Completed	Healthy Volunteers\|Oncology Solid Tumor Unspecified	2023-03-13		2025-04-29

Recent News Events

Date	Type	Title
01/01/2024	PubMed	Food Effect on the Pharmacokinetics of VC004, a Tropomyosin Receptor Kinase Inhibitor: A Randomized Crossover Trial in Healthy Chinese Subjects.
01/01/2024	PubMed	ETV6::NTRK3 gene fusion in a patient with metastatic lung atypical carcinoid successfully treated with repotrectinib: A case report.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

VC-004

Alternative Names: vc-004, vc 004, vc004 Clinical Status: Active Latest Update: 2025-03-20 Latest Update Note: Clinical Trial Update